毒性試験のアウトソーシングの世界市場

毒性試験のアウトソーシングの世界市場は2030年までに56億米ドルに到達

2024年に36億米ドルと推定される毒性試験のアウトソーシングの世界市場は、2024年から2030年にかけてCAGR 7.5%で成長し、2030年には56億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるIn-Vitroは、CAGR 6.0%を記録し、分析期間終了時には31億米ドルに達すると予測されます。生体内セグメントの成長率は、分析期間でCAGR 9.6%と推定されます。

米国市場は9億8,060万米ドルと推定、中国はCAGR11.5％で成長予測

米国の毒性試験のアウトソーシング市場は、2024年に9億8,060万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.9%と7.1%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

毒性試験のアウトソーシング市場動向と促進要因のまとめ

毒性試験のアウトソーシングは医薬品の安全性と規制遵守をどのように強化しているか？

毒性試験は医薬品開発における重要なステップであり、新薬、化学物質、消費者製品の安全性と有効性を保証します。毒性試験を専門の開発業務受託機関（CRO）に委託することは、製薬会社やバイオテクノロジー企業にとって戦略的なアプローチとなっており、コスト削減、研究開発期間の短縮、厳しい規制要件の克服を可能にしています。安全性評価プロトコルの複雑化は、in vitroや計算機による毒性試験の進歩と相まって、外部専門家への需要を押し上げています。さらに、動物実験に代わる倫理的な代替法を求める動きは、臓器オンチップやAIを活用した予測モデリングの開発につながり、市場をさらに変化させています。しかし、データの完全性、標準化、異なる司法管轄区にまたがる規制遵守に関する懸念は依然として課題です。毒性試験が進化する中、アウトソーシング・パートナーシップはどのようにイノベーションを推進し、次世代治療薬の安全性を確保するのだろうか。

どのような技術革新が毒性試験のアウトソーシングを前進させているのか？

毒性試験における最先端の開発には、AIを活用した毒性予測モデル、ハイスループットスクリーニング（HTS）、ヒト臓器系を模倣した3D細胞培養モデルなどがあります。機械学習アルゴリズムは、膨大なデータセットを分析し、医薬品開発の初期段階で潜在的な安全性リスクを特定することで、毒性評価に革命をもたらしています。マイクロ流体臓器オンチップ・プラットフォームのようなin vitro試験法は、動物モデルへの依存を減らすと同時に、よりヒトに関連した毒性データを提供しています。さらに、ブロックチェーン技術は、データのトレーサビリティと規制遵守のために検討されており、世界の毒性試験ネットワーク全体の透明性と標準化を確保しています。

なぜ毒性試験のアウトソーシングの需要が高まっているのか？

医薬品の安全性に対する規制当局の監視の強化、医薬品開発パイプラインの複雑化、代替試験法の採用増加などが、毒性試験サービスのアウトソーシング需要を促進しています。製薬会社は、進化する安全性基準への準拠を確実にする費用対効果の高いソリューションを優先しています。さらに、個別化医療や生物製剤へのシフトにより、より専門的な毒性評価が必要となり、アウトソーシングの動向をさらに後押ししています。

毒性試験のアウトソーシング市場の成長を促進する要因とは？

予測毒性学の進歩、AIを活用した安全性評価ツールの採用拡大、化学物質や医薬品の安全性に関する規制要件の高まり、費用対効果の高いアウトソーシング・ソリューションに対する需要の高まりなどが、市場の拡大に寄与しています。医薬品開発企業が厳格な安全基準を満たしながら効率性の向上を目指す中、毒性試験におけるCROの役割は、医薬品開発と規制コンプライアンスの将来を形作る上でますます重要になると予想されます。

セグメント

試験法（in-vitro、in-vivo）;GLPタイプ（GLP、非GLP）;エンドユーザー（製薬・バイオファーマ企業、学術・研究機関、その他）

調査対象企業の例

• ALS Limited
• BioReliance（Merck KGaA）
• Catalent, Inc.
• Charles River Laboratories
• Covance Inc.（Labcorp Drug Development）
• Creative Bioarray
• Cyprotex（Evotec）
• Eurofins Scientific
• Evotec SE
• Frontage Laboratories
• GenScript Biotech Corporation
• ICON plc
• Intertek Group plc
• IQVIA
• Labcorp Drug Development
• Lonza Group
• Medpace, Inc.
• PPD, Inc.（Thermo Fisher Scientific）
• Promega Corporation
• SGS SA
• Syngene International Limited
• Toxikon Corporation

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Toxicity Testing Outsourcing Market to Reach US$5.6 Billion by 2030

The global market for Toxicity Testing Outsourcing estimated at US$3.6 Billion in the year 2024, is expected to reach US$5.6 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. In-Vitro, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the In-Vivo segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$980.6 Million While China is Forecast to Grow at 11.5% CAGR

The Toxicity Testing Outsourcing market in the U.S. is estimated at US$980.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 11.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Toxicity Testing Outsourcing Market Trends & Drivers Summarized

How Is Outsourcing Toxicity Testing Enhancing Drug Safety and Regulatory Compliance?

Toxicity testing is a critical step in drug development, ensuring the safety and efficacy of new pharmaceuticals, chemicals, and consumer products. Outsourcing toxicity testing to specialized contract research organizations (CROs) has become a strategic approach for pharmaceutical and biotechnology firms, allowing them to reduce costs, accelerate development timelines, and navigate stringent regulatory requirements. The increasing complexity of safety assessment protocols, coupled with advancements in in vitro and computational toxicity testing, is driving demand for external expertise. Additionally, the push for ethical alternatives to animal testing has led to the development of organ-on-a-chip and AI-driven predictive modeling, further transforming the market. However, concerns regarding data integrity, standardization, and regulatory compliance across different jurisdictions remain challenges. As toxicity testing evolves, how will outsourcing partnerships drive innovation and ensure the safety of next-generation therapeutics?

What Technological Innovations Are Advancing Toxicity Testing Outsourcing?

Cutting-edge developments in toxicity testing include AI-powered toxicity prediction models, high-throughput screening (HTS), and 3D cell culture models that mimic human organ systems. Machine learning algorithms are revolutionizing toxicity assessment by analyzing vast datasets and identifying potential safety risks early in drug development. In vitro testing methods, such as microfluidic organ-on-a-chip platforms, are reducing reliance on animal models while providing more human-relevant toxicity data. Additionally, blockchain technology is being explored for data traceability and regulatory compliance, ensuring transparency and standardization across global toxicity testing networks.

Why Is the Demand for Toxicity Testing Outsourcing Increasing?

The growing regulatory scrutiny of pharmaceutical safety, increasing complexity of drug development pipelines, and rising adoption of alternative testing methods are driving demand for outsourced toxicity testing services. Pharmaceutical companies are prioritizing cost-effective solutions that ensure compliance with evolving safety standards. Additionally, the shift toward personalized medicine and biologics is requiring more specialized toxicity evaluation, further boosting outsourcing trends.

What Factors Are Driving the Growth of the Toxicity Testing Outsourcing Market?

The market is expanding due to advancements in predictive toxicology, increasing adoption of AI-driven safety assessment tools, growing regulatory requirements for chemical and pharmaceutical safety, and rising demand for cost-effective outsourcing solutions. As drug developers seek to improve efficiency while meeting strict safety standards, the role of CROs in toxicity testing is expected to become increasingly vital in shaping the future of drug development and regulatory compliance.

SCOPE OF STUDY:

The report analyzes the Toxicity Testing Outsourcing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Method (In-Vitro, In-Vivo); GLP Type (GLP, Non-GLP); End-Use (Pharma & Biopharma Companies, Academic & Research Institutes, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• ALS Limited
• BioReliance (Merck KGaA)
• Catalent, Inc.
• Charles River Laboratories
• Covance Inc. (Labcorp Drug Development)
• Creative Bioarray
• Cyprotex (Evotec)
• Eurofins Scientific
• Evotec SE
• Frontage Laboratories
• GenScript Biotech Corporation
• ICON plc
• Intertek Group plc
• IQVIA
• Labcorp Drug Development
• Lonza Group
• Medpace, Inc.
• PPD, Inc. (Thermo Fisher Scientific)
• Promega Corporation
• SGS SA
• Syngene International Limited
• Toxikon Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Toxicity Testing Outsourcing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Regulatory Scrutiny and Safety Requirements Drive Toxicity Testing Demand
  • Growth in Biopharmaceutical and Agrochemical Pipelines Fuels Outsourcing of Preclinical Testing
  • Cost and Time Pressures Push Sponsors to Engage Specialized CROs for Toxicology Studies
  • Shift Toward In Vitro and Alternative Testing Models Supports Innovation in Assay Platforms
  • Increasing Adoption of High-Throughput Screening Enhances Outsourcing Efficiency
  • Expansion of GLP-Compliant Testing Facilities Across Asia-Pacific Improves Global Access
  • Complexity of Multi-Species and Long-Term Studies Encourages Outsourced Execution
  • Advancements in Organoids and Organ-on-a-Chip Models Gain CRO Integration
  • AI-Based Predictive Toxicology Platforms Strengthen Risk Assessment Capabilities
  • Consolidation of CROs and CDMOs Supports End-to-End Toxicity and Regulatory Services
  • Growing Demand for Genetic, Reproductive, and Environmental Toxicity Testing Broadens Scope
  • Rising R&D in Cosmetics and Nutraceuticals Expands Demand for Non-Animal Safety Testing
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Toxicity Testing Outsourcing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Toxicity Testing Outsourcing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Toxicity Testing Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for In-Vitro by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for In-Vitro by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for In-Vitro by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for In-Vivo by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for In-Vivo by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for GLP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Non-GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Non-GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Non-GLP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• JAPAN
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• CHINA
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• EUROPE
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Toxicity Testing Outsourcing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Toxicity Testing Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• FRANCE
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• GERMANY
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Italy 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 101: UK Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: UK 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Spain 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 119: Russia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Russia Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Russia 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Europe 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Toxicity Testing Outsourcing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Asia-Pacific 15-Year Perspective for Toxicity Testing Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 149: Australia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Australia Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Australia 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• INDIA
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 158: India Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: India Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: India 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 161: India Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 167: South Korea Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: South Korea Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: South Korea 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Asia-Pacific Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 185: Latin America Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Latin America Historic Review for Toxicity Testing Outsourcing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Latin America 15-Year Perspective for Toxicity Testing Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 197: Argentina Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Argentina Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Argentina 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Brazil 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 215: Mexico Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Mexico Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Mexico 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Latin America 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 233: Middle East Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 234: Middle East Historic Review for Toxicity Testing Outsourcing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Middle East 15-Year Perspective for Toxicity Testing Outsourcing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 245: Iran Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Iran Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Iran 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Israel 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Saudi Arabia Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Saudi Arabia 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 272: UAE Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: UAE Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: UAE 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Rest of Middle East Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Rest of Middle East 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030
• AFRICA
  • Toxicity Testing Outsourcing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 290: Africa Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Africa Historic Review for Toxicity Testing Outsourcing by Method - In-Vitro and In-Vivo Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Africa 15-Year Perspective for Toxicity Testing Outsourcing by Method - Percentage Breakdown of Value Sales for In-Vitro and In-Vivo for the Years 2015, 2025 & 2030
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Toxicity Testing Outsourcing by GLP Type - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Toxicity Testing Outsourcing by GLP Type - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Toxicity Testing Outsourcing by End-Use - Pharma & Biopharma Companies, Academic & Research Institutes and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Toxicity Testing Outsourcing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies, Academic & Research Institutes and Others for the Years 2015, 2025 & 2030

IV. COMPETITION